Group items tagged

Asda Ramsgate pharmacy worker Claire Twyman saved life of a regular patient Rose Doyle by giving her a timely advice to visit A&E after spotting a blood clot on her leg. Doyle (75) spent five days in Margate Hospital, and after recovering she called in at the store to thank Twyman for her quick-thinking actions. She handed her a thank-you note which read: "Thank you for making me go to A&E. You may have saved my life, so thank you once again I am really grateful." Twyman, who has worked at the store for nine years, said: "I was just happy that I was able to help her and give her that advice, which made a difference. It could have been a lot worse if she'd left it. I'm so glad she's okay. "Rose came over to the pharmacy for advice on her leg. I looked down and told her it was really swollen, and then asked to look at her foot. I thought straightaway that it was a thrombosis, a blood clot. Her toes were very white, but I didn't want to alarm her."

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

Germany-based pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).